CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
(TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumote...
Phase 3
Pittsburgh, Pennsylvania, United States and 165 other locations
resectable gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma who have not received previous treatment for the disease....
Phase 2
Pittsburgh, Pennsylvania, United States and 56 other locations
The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitab...
Phase 3
Pittsburgh, Pennsylvania, United States and 132 other locations
and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma...
Phase 2
Pittsburgh, Pennsylvania, United States and 43 other locations
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.
Phase 3
Pittsburgh, Pennsylvania, United States and 57 other locations
esophageal adenocarcinoma.This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will b...
Phase 1, Phase 2
Pittsburgh, Pennsylvania, United States and 41 other locations
the treatment of participants with advanced or metastatic gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, o...
Phase 1, Phase 2
Pittsburgh, Pennsylvania, United States and 42 other locations
This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitiza...
Phase 2
Pittsburgh, Pennsylvania, United States and 68 other locations
after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponso...
Phase 3
Pittsburgh, Pennsylvania, United States and 217 other locations
in participants with untreated metastatic Pancreatic Ductal Adenocarcinoma (PDAC) with homozygous methylthioadenosine phosphorylase (MTAP) d...
Phase 2, Phase 3
Pittsburgh, Pennsylvania, United States and 258 other locations
Clinical trials
Research sites
Resources
Legal